16:28 EST Sangamo (SGMO) down 31% at $1.61 after Pfizer decision to terminate collaboration
Don't Miss Our New Year's Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on SGMO:
- Sangamo to regain rights to giroctocogene fitelparvovec from Pfizer
- Sangamo to receive $20M from Astellas Pharma in capsid license agreement
- Biotech Alert: Searches spiking for these stocks today
- Sangamo upgraded to Buy from Hold at Truist
- Sangamo Biosciences’ Legal Victory and Hemophilia Trial Success
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
